[
1. Bosevski M et al. Special Conditions in Venous Thromboembolism - Case Series. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2019 1;40(2):103-111. doi: 10.2478/prilozi-2019-0021. PMID: 31605581.31605581
]Open DOISearch in Google Scholar
[
2. Khan, S., Dickerman, J.D. Hereditary thrombophilia. Thrombosis J 4, 15 (2006). https://doi.org/10.1186/1477-9560-4-15159247916968541
]Search in Google Scholar
[
3. Cushman M, Epidemiology and Risk Factors for Venous Thrombosis. Semin Hematol. 2007 Apr; 44(2): 62–69.doi:10.1053/j.seminhematol.2007.02.004202080617433897
]Open DOISearch in Google Scholar
[
4. Varga E.A., Moll S. Prothrombin 20210 Mutation (Factor II Mutation). Circulation. 2004;110:e15– e18. doi:10.1161/01.CIR.0000135582.53444.8715262854
]Open DOISearch in Google Scholar
[
5. De Stefano V, Martinelli I, Mannucci P, et al. The risk of recurrent deep venous thromboembolism among heterozygous carriers of both Factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999; 341:801-806.10.1056/NEJM19990909341110410477778
]Search in Google Scholar
[
6. Nicolaides AN, Breddin HK, Carpentier P, et al. Thrombophilia and venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Int Angiol 2005;24:1–26.10.1177/00033197050560i10116193220
]Search in Google Scholar
[
7. Roldán V, Lecumberri R, Sánchez Muñoz-Torrero JF, et al. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Res 2009; 124(2): 174-7.
]Search in Google Scholar
[
8. Gabriel F, Portolés O, Labiós M et al. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE Registry. Clin Appl Thromb Hemost 2013; 19(1): 42-7.10.1177/107602961143619322327823
]Search in Google Scholar
[
9. Rodger MA, Le Gal G. Who should get long-term anticoagulant therapy for venous thromboembolism and with what?. Blood Adv. 2018;2(21):3081-3087. doi:10.1182/bloodadvances.2018020230623437030425073
]Open DOISearch in Google Scholar
[
10. Fahrni J, Husmann M, Gretener SB et al. Assessing the risk of recurrent venous thromboembolism-a practical approach. Vasc Health Risk Manag. 2015;11:451-459. doi:10.2147/VHRM. S83718
]Open DOISearch in Google Scholar
[
11. Kearon C and Elie A. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism Akl2 1 Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada; and 2 Clinical Epidemiology Unit, American University of Beirut, Beirut, Lebanon https://doi.org/10.1182/blood-2013-12-51268124497538
]Search in Google Scholar
[
12. Kearon C, Akl EA, Omelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; https://doi.org/10.1016/j.chest.2015.11.02626867832
]Search in Google Scholar
[
13. Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012. 141 (2 Suppl):7S-47S.10.1378/chest.141.4.1129a
]Search in Google Scholar
[
14. Stavros V Konstantinides, Guy Meyer, Cecilia Becattini, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC), European Heart Journal 2020, Pages 543–603, https://doi.org/10.1093/eurheartj/ehz40531504429
]Search in Google Scholar
[
15. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: Analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036. DOI: 10.1136/bmj.d3036310075921610040
]Open DOISearch in Google Scholar
[
16. Couturaud F, Pernod F, Presles E, et al. Six Months Versus Two Years Of Oral Anticoagulation After A First Episode Of Unprovoked Deep-Vein Thrombosis. The PADIS-DVT Randomized Clinical Trial. Haematologica 2019 104: 1493-1501; Doi:10.3324/haematol.2018.210971660108930606789
]Open DOISearch in Google Scholar
[
17. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366:l4363.10.1136/bmj.l4363665106631340984
]Search in Google Scholar
